Carboplatin (AUC 5) Clinical Trials

6 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Pipeline

Phase 1: 1Phase 2: 4Phase 1/2: 1

Top Sponsors

Yang Hong1
Xijing Hospital1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1
Inhibrx Biosciences, Inc1
CatalYm GmbH1

Indications

Cancer6
Lung Cancer4
Advanced Gynecological Malignancies1
Stage IIIC Non-Small Cell Lung Cancer1
Stage IIIB Non-small Cell Lung Cancer1

Other4 trials

A Study of Ivonescimab in First-Line ES-SCLC

Phase 2

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Phase 1

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

Phase 2

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Phase 2

Birmingham, Alabama1 trial

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

University of Alabama at Birmingham

Phase 2

Duarte, California1 trial

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

City of Hope

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.